New HIV prevention shots for women: will they stay the course?
NCT ID NCT06145854
First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 25 times
Summary
This study follows 100 cisgender women in the southern U.S. who are already using a long-acting injectable medication (cabotegravir) to prevent HIV. Researchers want to see how many women keep up with their shots over 44 weeks and how satisfied they are with the treatment. The goal is to understand if this easier, every-other-month option works well in real life for women at risk of HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Midway Specialty Care Center
Orlando, Florida, 32819, United States
-
Midway Specialty Care Center
Temple Terrace, Florida, 33617, United States
-
Midway Specialty Care Center
West Palm Beach, Florida, 33401, United States
Conditions
Explore the condition pages connected to this study.